Pathologic basis and treatment considerations in chronic kidney disease-related hypertension

Seminars in Nephrology

Volumn 25, Issue 4, 2005, Pages 246-251

  Sica, Domenic ^a   Carl, Dan ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMILORIDE; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; METOLAZONE; NADOLOL; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DISEASE CONTROL; DISEASE COURSE; ESSENTIAL HYPERTENSION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY CLEARANCE; KIDNEY TRANSPLANTATION; LETHARGY; PATHOGENESIS; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RENOVASCULAR HYPERTENSION; REVIEW; SEDATION; SIDE EFFECT; SLEEP APNEA SYNDROME; TREATMENT INDICATION;

EID: 22544479130     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2005.03.001     Document Type: Article

References (62)

1. US Renal Data System USRDS 2000 Annual Report 2000 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
2. Centers for Disease Control and Prevention State-specific trends in chronic kidney failure-United States, 1990-2001 MMWR Morb Mortal Wkly Rep 53 2001 918 920
3. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease Evaluation, classification and stratification Am J Kidney Dis 39 suppl 1 2002 S1 S266
4. L.U. Mailloux Hypertension in patients with chronic renal disease Am J Kidney Dis 32 suppl 3 1998 S120 S141
5. National Kidney Foundation K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 suppl 1 2004 S1 S290
6. L. De Nicola, R. Minutolo, V. Bellizzi Achievement of target blood pressure levels in chronic kidney disease A salty question? Am J Kidney Dis 43 2004 782 795
7. N. Vasavada, R. Agarwal Role of excess volume in the pathophysiology of hypertension in chronic kidney disease Kidney Int 64 2003 1772 1779
8. M.S. Neff, K.E. Kim, M. Persoff Hemodynamics of uremic anemia Circulation 43 1971 876 883
9. M.E. Safar, G.M. London, Y.A. Weiss Overhydration and renin in hypertensive patients with terminal renal failure; a hemodynamic study Clin Nephrol 5 1975 183 188
10. J.P. Kooman, F.M. Van Der Sande, K.M. Leunissen Role of sodium and volume in the pathogenesis of hypertension in dialysis patients. Reflections on pathophysiological mechanisms Blood Purif 22 2004 55 59
11. L.U. Mailloux Hypertension in chronic renal failure and ESRD Prevalence, pathophysiology, and outcomes Semin Nephrol 21 2001 146 156
12. R. Agarwal Proinflammatory effects of oxidative stress in chronic kidney disease Role of additional angiotensin II blockade Am J Physiol 284 2003 F863 F869
13. R. Lariviere, M. Lebel Endothelin-1 in chronic renal failure and hypertension Can J Physiol Pharmacol 81 2003 607 621
14. E.M. Freel, J.M. Connell Mechanisms of hypertension the expanding role of aldosterone J Am Soc Nephrol 15 2004 1993 2001
15. N. McLaughlin, T.W.B. Gehr, D.A. Sica Aldosterone receptor antagonism and end-stage renal disease Curr Hypertens Rep 6 2004 327 330
16. A. Sato, K. Hayashi, T. Saruta Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease Am J Hypertens 18 2005 44 49
17. M. Epstein, V. Buckalew, F. Martinez Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria Am J Hypertens 15 suppl 1 2002 A24
18. V.M. Campese, M.S. Romoff, D. Levitan Mechanisms of autonomic nervous system dysfunction in uremia Kidney Int 20 1981 246 253
19. J. Neumann, G. Ligtenberg, I.I. Klein Sympathetic hyperactivity in chronic kidney disease Pathogenesis, clinical relevance, and treatment Kidney Int 65 2004 1568 1576
20. K. Laederach, P. Weidmann Plasma and urinary catecholamines in relation to renal function in man Kidney Int 31 1987 107 111
21. R.L. Converse Jr, T.N. Jacobsen, R.D. Toto Sympathetic overactivity in patients with chronic renal failure N Engl J Med 327 1992 1912 1918
22. I. Odar-Cederlof, F. Ericcson, E. Theodorsson Is neuropeptide Y a contributor to volume-induced hypertension Am J Kidney Dis 31 1998 803 808
23. C. Zoccali, F. Mallamaci, G. Tripepi Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease J Hypertens 21 2003 1355 1362
24. P.S. Modlinger, C.S. Wilcox, S. Aslam Nitric oxide, oxidative stress, and progression of chronic renal failure Semin Nephrol 24 2004 354 365
25. C. Zoccali, F. Mallamaci, G. Tripepi Novel cardiovascular risk factors in end-stage renal disease J Am Soc Nephrol 15 2004 S77 S80
26. J.T. Kielstein, R.H. Boger, S.M. Bode-Boger Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease Relationship to treatment method and atherosclerotic disease J Am Soc Nephrol 10 1999 594 600
27. M. Scroider, E. Riedel, W. Beck Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes Kidney Int 78 suppl 1 2001 S19 S24
28. M. Nishimura, H. Takahashi, K. Maruyama Enhanced production of nitric oxide may be involved in acute hypotension during maintenance hemodialysis Am J Kidney Dis 31 1998 809 817
29. U.M. Khosla, R.J. Johnson Hypertension in hemodialysis patients and the "lag phenomenon" insights into pathophysiology and clinical management Am J Kidney Dis 43 2004 739 751
30. C. Avendano, J.S. Alvarez, J.A. Sacristan Interference of digoxin-like immunoreactive substances with TDx digoxin II assay in different patients Ther Drug Monit 13 1991 523 527
31. J.E. Bisordi, S. Holt Digitalis-like immunoreactive substances and extracellular fluid volume status in chronic hemodialysis patients Am J Kidney Dis 13 1989 396 403
32. S.G. Rostand, T.B. Drueke Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure Kidney Int 56 1999 383 392
33. H. Ogata, E. Ritz, G. Odoni Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors J Am Soc Nephrol 14 2003 959 967
34. R.J. Johnson, D.I. Feig, J. Herrera-Acosta Resurrection of uric acid as a causal risk factor in essential hypertension Hypertension 45 2005 18 20
35. D.H. Kang, T. Nakagawa Uric acid and chronic renal disease Possible implication of hyperuricemia on progression of renal disease Semin Nephrol 25 2005 43 49
36. M. Mazzali, J. Hughes, Y.G. Kim Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism Hypertension 38 2001 1101 1106
37. L.G. Sánchez-Lozada, E. Tapia, J. Santamaria Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats Kidney Int 67 2005 237 247
38. S. Watanabe, D.H. Kang, L. Feng Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity Hypertension 40 2002 355 360
39. D.A. Sica, A. Schoolwerth Uric acid and losartan Curr Opin Nephrol Hypertens 11 2002 475 482
40. K.P. Parker Sleep disturbances in dialysis patients Sleep Med Rev 7 2003 131 143
41. C. Zoccali, F. Mallamaci, G. Tripepi Sleep apnea in renal patients J Am Soc Nephrol 12 2001 2854 2859
42. D. Crabtree, B. Morgan, J. Skatrud Chemoreflex sensitization augments sympathetic vasomotor outflow in awake humans Am Rev Respir Dis 147 1993 A1015 (abstr)
43. S.C. Textor Ischemic nephropathy Where are we now? J Am Soc Nephrol 15 2004 1974 1982
44. S.C. Textor, A.C. Novick, D.R. Steinmuller Renal failure limiting antihypertensive therapy as an indication for renal revascularization Arch Intern Med 143 1983 2208 2211
45. Y.W. Lam, S. Banerji, C. Hatfield Principles of drug administration in renal insufficiency Clin Pharmacokinet 32 1997 30 57
46. A.J. Olyaei, A.M. De Mattos, W.M. Bennett Prescribing drugs in renal disease B. Brenner F. Rector The Kidney (6th ed) 2000 WB Saunders Philadelphia 2606 2653
47. D.A. Sica Kinetics of angiotensin converting enzyme inhibitors in renal failure J Cardiovasc Pharmacol 20 suppl 10 1992 S13 S20
48. W.H. Frishman, M. Alwarshetty β-adrenergic blockers in systemic hypertension Clin Pharmacokinet 41 2002 505 516
49. G.L. Bakris, M. Williams, L. Dworkin National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Preserving renal function in adults with hypertension and diabetes A consensus approach Am J Kidney Dis 36 2000 646 661
50. H.T. Yu Progression of chronic renal failure Arch Intern Med 163 2003 1417 1429
51. D. de Zeeuw, G. Remuzzi, H.H. Parving Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy Lessons from RENAAL Kidney Int 65 2004 2309 2320
52. C. Aros, G. Remuzzi The renin-angiotensin system in progression, remission and regression of chronic nephropathies J Hypertens 20 suppl 3 2002 S45 S53
53. J. Coresh, B. Astor, M.J. Sarnak Evidence for increased cardiovascular disease risk in patients with chronic kidney disease Curr Opin Nephrol Hypertens 13 2004 73 81
54. F. Locatelli, L. Del Vecchio, P. Pozzoni Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies? Kidney Int 93 suppl 1 2005 S15 S19
55. M.J. Sarnak, T. Greene, X. Wang The effect of a lower target blood pressure on the progression of kidney disease Long-term follow-up of the modification of diet in renal disease study Ann Intern Med 142 2005 342 351
56. A.K. Bidani, K.A. Griffin Pathophysiology of hypertensive renal damage Implications for therapy Hypertension 44 2004 595 601
57. E. Mentari, M. Rahman Blood pressure and progression of chronic kidney disease Importance of systolic, diastolic, or diurnal variation Curr Hypertens Rep 6 2004 400 404
58. H. Buter, M.H. Hemmelder, G. Navis The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide Nephrol Dial Transplant 13 1998 1682 1685
59. D.A. Sica, T.W. Gehr Diuretic use in stage 5 chronic kidney disease and end-stage renal disease Curr Opin Nephrol Hypertens 12 2003 483 490
60. D.A. Sica Metolazone and its role in edema management Congest Heart Fail 9 2003 100 105
61. M. Epstein Role of aldosterone blockade in the management of hypertension and cardiovascular disease Contrib Nephrol 143 2004 90 104
62. D.A. Sica Eplerenone: A new aldosterone receptor antagonist: Are the FDA's restrictions appropriate J Clin Hypertens 4 2002 441 445